Artelo Biosciences Inc ARTL
NASDAQ · United States · Health Technology
$3.83-0.21 (-5.20%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks Application expands Artelo’s intellectual property position for ART27.13 into obesity, where J.P. Morgan has projected the global GLP-1 market could reach $200 billion by 2030 New findings show the combination further improved oral glucose tolerance and increased bone mineral density, an effect not observed in
Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic® and Wegovy® Combining ART27.13 with semaglutide produced approximately 40% weight loss – double that of semaglutide alone Results indicate that ART27.13 may possess the profile of a “metabolic regulator” capable of differentially modifying body weight and other parameters depending on the metabolic phenotype being treated SOLANA B
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.